The functional repertoire of rabbit antibodies and antibody discovery via next-generation sequencing.
To gain insight into the functional antibody repertoire of rabbits, the VH and VL repertoires of bone marrow (BM) and spleen (SP) of a naïve New Zealand White rabbit (NZW; Oryctolagus cuniculus) and that of lymphocytes collected from a NZW rabbit immunized (IM) with a 16-mer peptide were deep-sequenced. Two closely related genes, IGHV1S40 (VH1a3) and IGHV1S45 (VH4), were found to dominate (~90%) the VH repertoire of BM and SP, whereas, IGHV1S69 (VH1a1) contributed significantly (~40%) to IM. BM and SP antibodies recombined predominantly with IGHJ4. A significant proportion (~30%) of IM sequences recombined with IGHJ2. The VK repertoire was encoded by nine IGKV genes recombined with one IGKJ gene, IGKJ1. No significant bias in the VK repertoire of the BM, SP and IM samples was observed. The complementarity-determining region (CDR)-H3 and -L3 length distributions were similar in the three samples following a Gaussian curve with average length of 12.2 ± 2.4 and 11.1 ± 1.1 amino acids, respectively. The amino acid composition of the predominant CDR-H3 and -L3 loop lengths was similar to that of humans and mice, rich in Tyr, Gly, Ser and, in some specific positions, Asp. The average number of mutations along the IGHV/KV genes was similar in BM, SP and IM; close to 12 and 15 mutations for VH and VL, respectively. A monoclonal antibody specific for the peptide used as immunogen was obtained from the IM rabbit. The CDR-H3 sequence was found in 1,559 of 61,728 (2.5%) sequences, at position 10, in the rank order of the CDR-H3 frequencies. The CDR-L3 was found in 24 of 11,215 (0.2%) sequences, ranking 102. No match was found in the BM and SP samples, indicating positive selection for the hybridoma sequence. Altogether, these findings lay foundations for engineering of rabbit V regions to enhance their potential as therapeutics, i.e., design of strategies for selection of specific rabbit V regions from NGS data mining, humanization and design of libraries for affinity maturation campaigns.
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Sreekumar
S
Kodangattil
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Christine
C
Huard
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Cindy
C
Ross
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Jian
J
Li
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Huilan
H
Gao
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Alessandro
A
Mascioni
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Santosh
S
Hodawadekar
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Snehal
S
Naik
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Jessica
J
Min-debartolo
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Alberto
A
Visintin
CTI-Boston; Pfizer Inc.; Boston, MA USA.
Juan C
JC
Almagro
D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies / Q000235:genetics* / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology; D001853:Bone Marrow / Q000276:immunology; D022801:Complementarity Determining Regions / Q000235:genetics; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D007114:Immunization; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D007147:Immunoglobulin Light Chains / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D051379:Mice; D008969:Molecular Sequence Data; D009154:Mutation; D010455:Peptides / Q000276:immunology; D015202:Protein Engineering; D011817:Rabbits / Q000235:genetics* / Q000276:immunology*; D017386:Sequence Homology, Amino Acid; D013154:Spleen / Q000276:immunology
D000906:Antibodies; D000911:Antibodies, Monoclonal; D022801:Complementarity Determining Regions; D007143:Immunoglobulin Heavy Chains; D007147:Immunoglobulin Light Chains; D007135:Immunoglobulin Variable Region; D010455:Peptides
antibody gene usage; antigen-binding site; immunogobulins; therapeutic antibodies